Celldex Therapeutics Ownership | Who Owns Celldex Therapeutics?


OverviewForecastRevenueFinancialsChart

Celldex Therapeutics Ownership Summary


Celldex Therapeutics is owned by 128.62% institutional investors, 0.27% insiders. Wellington management group llp is the largest institutional shareholder, holding 14.34% of CLDX shares. Vanguard Health Care Inv is the top mutual fund, with 5.45% of its assets in Celldex Therapeutics shares.

CLDX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCelldex Therapeutics128.62%0.27%-28.89%
SectorHealthcare Stocks 50.59%12.40%37.01%
IndustryBiotech Stocks 49.10%12.14%38.76%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Wellington management group llp9.54M14.34%$355.12M
Blackrock funding, inc. /de7.00M10.52%$260.56M
Kynam capital management, lp5.32M8.00%$198.07M
Blackrock4.69M7.97%$173.61M
Price t rowe associates inc /md/4.69M7.04%$174.34M
Vanguard group4.03M6.06%$109.38M
State street3.90M5.86%$145.13M
Fmr3.72M5.59%$138.53M
Vanguard capital management3.46M5.21%$128.93M
Deep track capital, lp2.94M4.42%$109.37M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Kynam capital management, lp5.32M10.95%$198.07M
Superstring capital management lp287.58K6.76%$10.70M
5am venture management497.27K6.43%$18.50M
Foresite capital management vi879.71K5.09%$32.73M
Eversept partners, lp1.79M3.45%$66.45M
Logos global management lp2.10M3.36%$78.14M
Tsp capital management group371.13K3.30%$13.81M
Commodore capital lp1.35M2.99%$50.23M
Rosalind advisors200.00K2.76%$7.44M
Novo1.02M2.21%$38.14M

Top Buyers

HolderShares% AssetsChange
Price t rowe associates inc /md/4.69M0.02%2.60M
Deep track capital, lp2.94M1.59%1.66M
Logos global management lp2.10M3.36%1.65M
Blackrock funding, inc. /de7.00M0.00%1.63M
State street3.90M0.00%1.10M

Top Sellers

HolderShares% AssetsChange
Point72 asset management117.22K0.00%-3.11M
T. rowe price investment management---1.70M
Commodore capital lp1.35M2.99%-1.35M
Jennison associates---1.32M
Vestal point capital, lp---1.22M

New Positions

HolderShares% AssetsChangeValue
Driehaus capital management989.44K0.21%989.44K$36.82M
Sixth street partners management company655.95K0.00%655.95K$24.41M
Federated hermes492.89K0.03%492.89K$18.34M
Trexquant investment lp184.52K0.04%184.52K$6.87M
Axa investment managers121.33K0.01%121.33K$3.14M

Sold Out

HolderChange
Umb bank, n.a.-2.00
Strategic investment solutions, inc. /il-5.00
Scarborough advisors-6.00
Mai capital management-8.00
Nelson, van denburg & campbell wealth management group-10.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202626814.53%85,613,85817.37%1281.07%15824.41%57-1.72%
Mar 31, 202623022.99%72,850,785-0.75%1090.90%12449.40%58-3.33%
Dec 31, 2025112-41.05%27,037,989-61.77%400.36%48-51.02%35-31.37%
Sep 30, 20251802.27%69,405,041-0.96%1040.94%95-14.41%5031.58%
Jun 30, 20251843.95%72,686,2280.53%1090.92%11325.56%41-22.64%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Health Care Inv4.28M5.45%-
BB Biotech AG Ord3.56M5.34%250.10K
Vanguard MStar Total Stk Mkt Idx Invest2.50M3.19%13.41K
Vanguard Total Stock Mkt Idx Inv2.49M3.17%30.39K
Vanguard Morn Total Stk Mkt Idx Investor2.49M3.17%30.39K
Vanguard US Total Market Shares ETF2.07M3.11%2.12K
iShares Russell 2000 ETF1.99M2.54%-35.42K
State Street® SPDR® S&P® Biotech ETF1.99M2.53%4.57K
Vanguard Explorer Inv1.45M1.84%390.07K
Polar Capital Healthcare Opports Inc1.15M1.73%-

Recent Insider Transactions


DateNameRoleActivityValue
Dec 04, 2025Jimenez Freddy A. SVP & GENERAL COUNSELSell$121.21K
Nov 13, 2025Wright Richard M. Former OfficerSell$1.18M
Aug 13, 2025Jimenez Freddy A. SVP & GENERAL COUNSELSell$8.17K
Aug 13, 2025Jimenez Freddy A. SVP & GENERAL COUNSELSell$10.93K
Nov 11, 2024Marucci Anthony S PRESIDENT & CEOBuy$308.43K

Insider Transactions Trends


DateBuySell
2025 Q4-2
2025 Q3-2
2025 Q2--
2024 Q41-
2024 Q2-12

CLDX Ownership FAQ


Who Owns Celldex Therapeutics?

Celldex Therapeutics shareholders are primarily institutional investors at 128.62%, followed by 0.27% insiders and -28.89% retail investors. The average institutional ownership in Celldex Therapeutics's industry, Biotech Stocks , is 49.10%, which Celldex Therapeutics exceeds.

Who owns the most shares of Celldex Therapeutics?

Celldex Therapeutics’s largest shareholders are Wellington management group llp (9.54M shares, 14.34%), Blackrock funding, inc. /de (7M shares, 10.52%), and Kynam capital management, lp (5.32M shares, 8.00%). Together, they hold 32.85% of Celldex Therapeutics’s total shares outstanding.

Does Blackrock own Celldex Therapeutics?

Yes, BlackRock owns 7.97% of Celldex Therapeutics, totaling 4.69M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 173.61M$. In the last quarter, BlackRock increased its holdings by 178.84K shares, a 3.96% change.

Who is Celldex Therapeutics’s biggest shareholder by percentage of total assets invested?

Kynam capital management, lp is Celldex Therapeutics’s biggest shareholder by percentage of total assets invested, with 10.95% of its assets in 5.32M Celldex Therapeutics shares, valued at 198.07M$.

Who is the top mutual fund holder of Celldex Therapeutics shares?

Vanguard Health Care Inv is the top mutual fund holder of Celldex Therapeutics shares, with 5.45% of its total shares outstanding invested in 4.28M Celldex Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools